COVID and venous thrombosis: systematic review of literature

Introduction: We aimed to review the prevalence, the risk factors and the outcomes of venous thrombosis (VT) in patients hospitalized for COronaVirus Disease 19 (COVID-19).
Evidence Acquisition: Electronic bibliographic databases were searched using the words “COVID venous thrombosis”. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement standards…

COVID-19 Boosters This Fall to Include Omicron Antigen, but Questions Remain About Its Value

Probably many people who watched or participated in the June 28 virtual US Food and Drug Administration (FDA) advisory committee meeting about updating COVID-19 vaccines could agree on 1 point, made by the agency’s Peter Marks, MD, PhD: “It is science at its hardest.” The FDA convened its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss whether to add an Omicron component to boosters for the fall….

Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review

The COVID-19 pandemic saw one of the fastest developments of vaccines in an effort to combat an out-of-control pandemic. The 2 most common COVID-19 vaccine platforms currently in use, messenger RNA (mRNA) and adenovirus vector, were developed on the basis of previous research in use of this technology…

SVM Communications: Vaccine-induced immune thrombotic thrombocytopenia (VITT) – what the vascular medicine physician should know

The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the rapid development of highly effective vaccines, which have proven to be the most important tool in combating the coronavirus disease 2019 (COVID-19) pandemic. Initial clinical trials reported no major adverse events beyond rare cases of anaphylaxis…

Complicanze tromboemboliche post-vaccinazione anti-COVID-19 con Vaxzevria (ChAdOx1 nCov-19, AstraZeneca) o con COVID-19 Vaccine Janssen (Ad.26. COV2.S, Johnson & Johnson)

In soggetti recentemente sottoposti a vaccinazione anti-SARS-CoV-2 con i vaccini a vettore virale Vaxzevria (ChAdOx1 nCov-19 della ditta Astra Zeneca) e con COVID-19 Vaccine Janssen (Ad.26.COV2.S della ditta Johnson & Johnson) sono state riportate diverse segnalazioni di eventi trombotici in sedi atipiche (trombosi dei seni venosi cerebrali e/o del distretto splancnico), associati a piastrinopenia e con decorsi clinici di particolare gravità…

Echocardiography, lung ultrasound, and cardiac magnetic resonance findings in COVID-19: A systematic review

The manifestations of COVID-19 as outlined by imaging modalities such as echocardiography, lung ultrasound (LUS), and cardiac magnetic resonance (CMR) imaging are not fully described. We conducted a systematic review of the current literature and included studies that described cardiovascular manifestations of COVID-19 using echocardiography, CMR, and pulmonary manifestations using LUS…

The vascular side of COVID-19 disease

The SARS-CoV-2 infection (COVID-19) is causing an ongoing pandemic and potentially fatal disease. Development of coagulopathy with thrombotic complications such as deep vein thrombosis and pulmonary embolism are emerging as factors for progression to severe disease and death. Also, a markedly increased level of D-dimer, a protein product of fibrin degradation, has been associated to mortality…

Acute Ischemic Stroke and COVID-19

Acute ischemic stroke may occur in patients with coronavirus disease 2019 (COVID-19), but risk factors, in-hospital events, and outcomes are not well studied in large cohorts. We identified risk factors, comorbidities, and outcomes in patients with COVID-19 with or without acute ischemic stroke and compared with patients without COVID-19 and acute ischemic stroke.

SARS-CoV-2 Vaccines

Shortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein (particularly in its prefusion [native] conformation) was identified as the immunodominant antigen of the virus. Evaluation of patients with SARS-CoV-2 revealed that binding and neutralizing antibodies primarily target the receptor-binding domain of the S1 subunit…

The Heart in COVID-19. Primary Target or Secondary Bystander?

In the throes of the current coronavirus disease-2019 (COVID-19) pandemic, interest has burgeoned in the cardiovascular complications of this virulent viral infection. As troponin, a biomarker of cardiac injury, often rises in hospitalized patients, its interpretation and actionability require careful consideration. Fulminant myocarditis due to direct viral infection can certainly occur, but in patients with increased oxygen demands due to tachycardia and fever and reduced oxygen delivery due to hypotension and hypoxemia, COVID-19 disease can cause myocardial injury indirectly…

Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era

It is clear that existing cardiovascular disease is a major risk factor for COVID-19 and related adverse outcomes. In addition to acute respiratory syndrome, a large cohort also develop myocardial or vascular dysfunction, in part from inflammation and renin angiotensin system activation with increased sympathetic outflow, cardiac arrhythmias, ischemia, heart failure, and thromboembolic complications that portend poor outcomes related to COVID-19…

Covid e Cuore: le molte facce del problema

L’insufficienza respiratoria acuta configurata dalla SARS CoV2 può determinare danno miocardico ipossico, testimoniato dal rilascio di biomarcatori come la troponina I ed i peptidi natriuretici. Ciò è particolarmente frequente quando i profili di comorbidità condizionano coronaropatie o ipertrofia miocardica o cardiopatie di varia eziologia…